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Abstract Canagliflozin (Invokana
®
) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various 
countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D). Unlike many T2D therapies, 
canagliflozin lowers blood glucose levels independently of insulin, with the inhibition of SGLT2 reducing renal 
reabsorption of glucose and increasing excretion of glucose in the urine. In well-designed clinical trials, canagliflozin 
(as first-line monotherapy or add-on therapy to other antihyperglycaemic agents) improved glycaemic control in adults 
with T2D, including those of older age and/or at high cardiovascular (CV) risk, and also had beneficial effects on their 
bodyweight and BP; whether the drug impacts the CV risk profile of T2D is currently being evaluated in the large CV 
outcomes study CANVAS. Canagliflozin was generally well tolerated, had a low risk of hypoglycaemia and was most 
commonly associated with adverse events such as genital and urinary tract infections and increased urination, consistent 
with its mechanism of action. Thus, canagliflozin is a useful monotherapy and add-on therapy option for the 
management of T2D in adults, and its CV profile is eagerly awaited. 
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Canagliflozin: clinical considerations in type 2 
diabetes 
Lowers blood glucose levels by increasing urinary 
glucose excretion, an effect independent of insulin 
Provides effective glycaemic control as first-line 
monotherapy or as add-on therapy 
Associated with reductions in bodyweight and BP 
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1 Introduction 
Type 2 diabetes (T2D) is a chronic progressive metabolic disease characterized by hyperglycaemia, due to insulin 
resistance/insufficient insulin production [1]. Patients are often obese, have lipid disturbances and elevated BP, and are 
at an increased risk of microvascular and macrovascular complications [1]. Achieving good glycaemic control [e.g. 
HbA1C level <7%] is a key management goal, for which numerous antihyperglycaemic agents (AHAs) with varying 
mechanisms of action are now available [2]. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a relatively recent 
AHA class. By inhibiting SGLT2 (a key protein in glucose resorption in the kidney), these drugs increase urinary 
glucose excretion (UGE), causing blood glucose levels to decline independently of insulin. One of the most widely 
available SGLT2 inhibitors is canagliflozin (Invokana
®
), which is approved for the treatment of T2D in various 
countries worldwide, including the USA and EU. This article reviews data relevant to the use of canagliflozin in T2D in 
the EU; fixed-dose canagliflozin/metformin tablets are also now available but are beyond the scope of this article. 
2 Pharmacodynamic Properties 
Canagliflozin is a potent competitive inhibitor of SGLT2 [3, 4], and thus reduces both renal glucose reabsorption and 
the renal threshold for glucose (RTG), with subsequent increases in UGE [5-7]. These increases in UGE reduce plasma 
glucose levels [5-7], provide calorie and thus bodyweight loss (Sect. 4.2) and have an osmotic diuretic effect (that may 
reduce BP; Sect. 4.3) [7], although transient early increases in urine output with canagliflozin may also reflect increased 
natriuresis [8]. Maximal RTG suppression in T2D patients was seen with canagliflozin 300 mg/day in phase 1 trials, 
with 24-h mean RTG values reduced from ≈13 to 4–5 mmol/L (i.e. values greater than plasma glucose levels usually 
associated with hypoglycaemia symptoms, indicating a low hypoglycaemia risk; Sect. 5.3) [7]. 
Canagliflozin is highly selective for SGLT2 in vitro [3, 4], with one study, for instance, demonstrating ≈200-fold 
greater affinity of the drug for SGLT2 than SGLT1 [3]. However, as SGLT1 is key in gastrointestinal glucose 
absorption, canagliflozin in the small intestines after oral administration may transiently inhibit intestinal SGLT1, and 
thus glucose absorption [9]. Indeed, in small placebo-controlled crossover studies in T2D patients [10] or healthy 
volunteers [11], canagliflozin reduced postprandial glucose (PPG) excursions by both non-renal (possibly via intestinal 
SGLT1 inhibition) and renal (via SGLT2 inhibition) mechanisms. Notably, canagliflozin 300 mg/day was associated 
with less extensive PPG excursions, lower 24-h mean RTG and greater 24-h UGE than dapagliflozin 10 mg/day in 
healthy volunteers [12]. Various measures of β-cell function improved with canagliflozin regimens in T2D trials [7, 13-
17], likely as an indirect consequence of reduced glucotoxicity.  
Canagliflozin (100 or 300 mg/day) was generally associated with small changes in serum electrolytes (including 
sodium, calcium, bicarbonate, phosphate, potassium and magnesium) [18], normalization of serum magnesium levels in 
hypomagnesaemia [19], and reductions in serum uric acid levels (possibly via increased urinary uric acid excretion) 
[20] in pooled (post hoc [19, 20]) analyses of phase 3 trials in T2D patients. The most common serum electrolyte 
abnormality of interest with canagliflozin 100 or 300 mg/day was potassium above the upper limit of normal plus >15% 
increase from baseline, both in patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2 (5 and 
7 vs. 5% of placebo recipients) and in those with an eGFR ≥45 to <60 mL/min/1.73m2 (5 and 9 vs. 6%) [18]. 
Elderly patients with T2D who added canagliflozin to their current AHA regimen in a phase 3 study (Sect. 4.4.2) 
had small but significant reductions in BMD at the total hip (but not other skeletal sites) over 104 weeks of therapy 
compared with adding placebo, with increases in biomarkers of bone turnover also seen over 52 weeks in the 
canagliflozin versus placebo groups; these changes were partly due to bodyweight loss, and bone strength was not 
impacted [21]. 
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3 Pharmacokinetic Properties 
Canagliflozin is rapidly absorbed after oral administration, reaching maximum plasma concentrations 1–2 h post-dose 
in T2D patients [5] and healthy volunteers [7]. The drug has a mean absolute oral bioavailability of ≈65% [22] and 
reaches steady-state in 4–5 days [5, 7]. Exposure increases in proportion to dose and there is up to 36% accumulation of 
the drug in plasma at the recommended dosages (100 or 300 mg/day) [5, 7]. Food does not impact canagliflozin 
pharmacokinetics [23], enabling it to be taken with or without food [7]; however, as canagliflozin may help reduce PPG 
excursions by delaying glucose absorption in the intestine (Sect. 2), administration before the first meal of the day is 
advised [7]. 
Canagliflozin is extensively (99%) plasma protein bound, and has a mean volume of distribution at steady state of 
83.5 L after intravenous infusion [7]. Metabolism of canagliflozin occurs primarily via O-glucuronidation (by UGT1A9 
and UGT2B4), producing two main inactive metabolites [24]; metabolism via CYP3A4 is minimal (≈7%) [7]. 
Canagliflozin is eliminated via the faeces (41.5% as parent drug; 10.2% as metabolites) and urine (33%, mainly O-
glucuronide metabolites), and recommended doses have renal clearance rates of 1.30–1.55 mL/min [7]. The mean 
elimination half-life of canagliflozin 100 or 300 mg/day in T2D patients was 13.7 and 14.9 h [5]. 
Mild or moderate hepatic impairment does not alter canagliflozin pharmacokinetics to a clinically relevant extent 
[25] and does not necessitate dosage adjustment [7]; the drug has not been assessed, and is thus not recommended, in 
severe hepatic impairment [7]. Renal impairment increases canagliflozin exposure and reduces pharmacodynamic 
response to the drug [25]. The canagliflozin dosage does not require adjustment in patients with an eGFR of 60 to <90 
mL/min/1.73 m
2
; however, if eGFR persistently declines below 60 or 45 mL/min/1.73 m
2
, dosage 
adjustment/consideration or discontinuation is necessary [7]. Canagliflozin should not be initiated in patients with an 
eGFR <60 mL/min/1.73 m
2 
or used in patients with end-stage renal disease/on dialysis. Renal function monitoring is 
advised [7]. 
Higher than therapeutic concentrations of canagliflozin did not inhibit or induce key CYP isoenzymes in vitro, and 
there was no clinically relevant impact of canagliflozin on CYP3A4 in vivo [7]. However, as canagliflozin is 
metabolized by UGT1A9 and UGT2B4, and transported by p-gp and BCRP, drugs that induce these enzymes may 
reduce canagliflozin exposure; thus, if coadministered, canagliflozin dosage adjustment (and, in some instances, 
additional AHAs) may be necessary [7]. There is also potential for canagliflozin exposure to be reduced by 
cholestyramine, necessitating staggered administration [7]. Canagliflozin weakly inhibits p-gp and may thus increase 
plasma concentrations of p-gp substrates; monitoring is advised [5, 7]. Intestinal BCRP inhibition by canagliflozin 
cannot be ruled out and may increase exposure to drugs transported by BCRP [7]. Canagliflozin may augment the 
effects of diuretics, increasing dehydration and hypotension (Sect. 5.2) risks [7]. There is also an increased risk of 
hypoglycaemia if canagliflozin is used in combination with an insulin secretagogue or insulin (Sect. 5.3); reduction of 
the insulin or insulin secretagogue dosage may be required [7]. 
4 Therapeutic Efficacy 
The clinical efficacy of oral canagliflozin, as monotherapy or add-on therapy, in adults with inadequately-controlled 
T2D, has been evaluated in numerous placebo- and/or active comparator-controlled trials of randomized, double-blind 
(or open-label [26]) design and 16–52-weeks’ duration; some studies also had 26- to 78-week double-blind extensions. 
Unless otherwise specified, trials were phase 3 and used the change from baseline in HbA1C (usually at 26 or 52 weeks; 
range 16–52 weeks) as the primary endpoint. Real-world data are also now available. Discussion focuses on 
recommended canagliflozin dosages (i.e. 100 or 300 mg/day); some data are from abstracts [27-32]. 
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 Glycaemic Parameters 4.1
In patients with T2D inadequately controlled by diet and exercise, monotherapy with canagliflozin 100 or 300 mg/day 
improved glycaemic control over 26 weeks, with each dosage significantly reducing HbA1C and FPG levels relative to 
placebo; the proportion of patients achieving an HbA1C target of <7% also significantly favoured the canagliflozin 
groups (Table 1) [13]. Improvements in glycaemic control were sustained over 52 weeks in canagliflozin recipients who 
continued to receive the drug in the 26-week extension of this trial (Table 1) [33]. Moreover, another study in this 
setting found canagliflozin 100 or 300 mg/day to be noninferior to metformin extended-release in improving HbA1C 
over 26 weeks (Table 1) [27].  
Canagliflozin was also an effective add-on therapy in patients with T2D inadequately controlled by their current 
AHA regimen. Indeed, as an add-on to metformin, canagliflozin 100 or 300 mg/day significantly improved HbA1C and 
other glycaemic parameters over 26 weeks relative to placebo (Table 2) [34]. Moreover, compared with adding 
sitagliptin [34] or glimepiride [35] in this setting, adding canagliflozin 100 mg/day was noninferior and adding 
canagliflozin 300 mg/day was superior in lowering HbA1C levels over 52 weeks (Table 2). A target HbA1C of <7.0% 
was reached by 41–60% of patients at 52 weeks in these trials (Table 2) [34, 35], with the odds of achieving this target 
without concomitant hypoglycaemia being 2.1- and 2.9-fold greater with canagliflozin 100 or 300 mg/day than with 
glimepiride (post hoc analysis) [28]. Reductions in FPG were also significantly [34] or numerically [35] greater in the 
canagliflozin than in the active comparator groups at 52 weeks in these studies (Table 2). Longer term, the relative 
glycaemic benefits of the canagliflozin and glimepiride regimens were generally sustained over up to 104 weeks’ 
therapy (Table 2) [36]. 
Similarly, in patients with T2D inadequately controlled by metformin plus either a sulfonylurea [14], pioglitazone 
[16] or sitagliptin [37], adding canagliflozin (100 or 300 mg/day) significantly lowered both HbA1C and FPG levels and 
significantly increased the proportion of patients achieving HbA1C levels <7% versus placebo over 26 weeks, with these 
benefits sustained up to 52 weeks [14, 16] (Table 2). Another trial in a similar patient population found adding 
canagliflozin 300 mg/day to metformin plus a sulfonylurea to be more effective in lowering HbA1C and FPG levels over 
52 weeks than adding sitagliptin, and numerically more canagliflozin than sitagliptin recipients achieved HbA1C <7% 
(Table 2) [15]. 
 Bodyweight 4.2
Canagliflozin (100 or 300 mg/day) significantly reduced bodyweight relative to placebo over 26 weeks, both when used 
as monotherapy in patients with T2D inadequately controlled by diet and exercise (Table 1) [13] and when used as add-
on therapy in patients whose T2D was inadequately controlled by metformin, either alone [34] or in combination with 
another oral AHA [14, 16, 37] (Table 2). In all settings, weight loss was sustained with canagliflozin up to 52 weeks 
(Table 1 and Table 2) [14, 16, 33, 34]. 
In active comparator-controlled trials, adding canagliflozin (100 or 300 mg/day) to ongoing metformin monotherapy 
[34, 35] or metformin plus a sulfonylurea [15] significantly reduced bodyweight over 52 weeks compared with adding 
either sitagliptin [15, 34] or glimepiride [35], with the benefit of canagliflozin versus glimepiride being maintained over 
104 weeks’ treatment [36] (Table 2). Notably, in a post hoc analysis [38] of one of these studies [35, 36], more 
overweight/obese patients (BMI ≥25 kg/m2) lost ≥4.5 kg in bodyweight with canagliflozin than with glimepiride over 
52 and 104 weeks. 
The weight loss associated with canagliflozin seems mainly due to fat mass reduction [35] and, according to a 
pooled analysis of four phase 3 placebo-controlled studies (n = 2250) [39], may contribute to some of the HbA1C- (Sect. 
4.1) and SBP- (Sect. 4.3) lowering benefits of the drug (≈15 and ≈42%, respectively). 
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 Other Parameters 4.3
In general, BP was modestly lowered with canagliflozin (as monotherapy or add-on therapy) in the trials discussed so 
far. For instance, in placebo-controlled studies [13, 14, 16, 34, 37], mean changes from baseline (126–131 mmHg) in 
SBP over 26 weeks ranged from −5.8 to −3.3 mmHg with canagliflozin (100 or 300 mg/day) versus −2.7 to +1.5 mmHg 
with placebo, with the between-group difference being statistically significant (p < 0.025) in all but one trial [14]. Mean 
changes from baseline (76–79 mmHg) in DBP in the respective groups ranged from −3.5 to −1.7 mmHg and from −1.7 
to +0.3 mmHg (p = 0.002 for canagliflozin vs. placebo, where reported/assessed [37]). Moreover, when four 26-week 
phase 3 placebo-controlled trials were pooled (n = 2313), the SBP- and DBP-lowering benefits of canagliflozin were 
seen regardless of whether antihypertensives were, or were not, taken concomitantly [40], and improvements in mean 
arterial pressure, pulse pressure and double product (a cardiac workload measure) were also seen with the drug [41]. 
In active comparator-controlled trials, adding canagliflozin (100 or 300 mg/day) to ongoing metformin monotherapy 
[34, 35] or metformin plus a sulfonylurea [15] reduced SBP over 52 weeks compared with adding either sitagliptin (p < 
0.001) [15, 34] or glimepiride (no p-value; comparison not prespecified) [35], with DBP-lowering benefits also evident 
in the canagliflozin versus the comparator groups. The SBP- and DBP-lowering effects of canagliflozin were durable, 
being sustained over 104 weeks of treatment [36]. 
In terms of lipids, canagliflozin (as monotherapy or add-on therapy) was generally associated with modest increases 
in HDL-C and LDL-C levels (with minimal LDL-C:HDL-C ratio changes) and modest reductions in triglyceride versus 
placebo over 26 weeks in key clinical trials (between-group differences were significant/numerical) [13, 14, 34, 37]; 
similar findings were generally seen at 52 weeks [14, 16, 33]. In active comparator-controlled trials, adding 
canagliflozin to metformin-based therapy for 52 weeks appeared to increase HDL-C levels [15, 34, 35] and (in some 
studies [15, 35]) LDL-C levels, relative to adding sitagliptin [15, 34] or glimepiride [35]. During this period, 
canagliflozin also reduced triglyceride levels relative to glimepiride [35], but did not significantly differ from sitagliptin 
in terms of triglyceride changes [15, 34]. Longer-term data from the glimepiride-controlled trial at 104 weeks were 
generally consistent with these findings [36]. 
In a post hoc analysis [42] of this trial [36], canagliflozin also appeared to preserve renal function relative to 
glimepiride over 104 weeks. The annual slope of eGFR decline was significantly (p < 0.01) smaller with canagliflozin 
100 or 300 mg/day than with glimepiride (0.5 and 0.9 vs. 3.3 mL/min/1.73 m
2
), with canagliflozin 300 mg/day (but not 
100 mg/day) also significantly (p < 0.01 vs. glimepiride) reducing the urinary albumin : creatinine ratio, independent of 
HbA1C changes [42]. 
 Special Patient Populations 4.4
The findings of trials and subgroup analyses assessing canagliflozin efficacy in various special patient groups are 
generally consistent with those of the pivotal trials already discussed; efficacy measures of particular relevance are 
summarized here.  
4.4.1 High CVD Risk Patients 
Clinical efficacy data for canagliflozin in patients with inadequately controlled T2D and an elevated risk of 
cardiovascular disease (CVD) are available from prespecified [43, 44] and post hoc [45] subgroup analyses of 
CANVAS, a trial designed primarily to assess the impact of canagliflozin on CVD risk [46]. In these patients, adding 
canagliflozin 100 or 300 mg/day to insulin ≥20 IU/day (with or without other AHAs) significantly improved HbA1C and 
FPG measures over 18 weeks relative to adding placebo, and these benefits were sustained to week 52 (Table 3); 
findings were independent of insulin dosage [43]. Similarly, adding canagliflozin 100 or 300 mg/day to ongoing 
6 E. D. Deeks 
 
   
 DRAFT MANUSCRIPT-CONFIDENTIAL. NOT FOR CIRCULATION TO THIRD PARTIES  
sulfonylurea monotherapy [44] or a DPP4 inhibitor or GLP-1 receptor agonist (RA), with or without other AHAs [45], 
improved glycaemic measures over 18 weeks versus adding placebo, although some subgroups were small (Table 3). 
Over 18–52 weeks, canagliflozin, compared with placebo, reduced bodyweight by up to 3.5 kg across subgroups (Table 
3) [43-45] and, in the largest substudy [43], reduced SBP and DBP and had minimal impact on the LDL-C: HDL-C 
ratio. 
These findings are generally supported by a post hoc pooled analysis of four 26-week placebo-controlled phase 3 
trials (n = 2313) in which canagliflozin (100 or 300 mg/day) regimens improved glycaemic control, bodyweight and 
SBP relative to placebo regardless of patient CVD history/risk factors [47]. 
4.4.2 Older Patients 
In older patients (n = 714) aged 55–80 years with T2D inadequately controlled by oral/injectable AHA regimens, 
adding canagliflozin 100 or 300 mg/day significantly (p < 0.001) improved glycaemic control over 26 weeks versus 
adding placebo, as measured by mean changes from baseline in HbA1C (−0.60 and −0.73 vs. −0.03%; overall baseline 
value 7.7% across groups) and FPG (−18.1 and −20.3 vs. +7.4 mmol/L; overall baseline value 157 mmol/L) levels [48]. 
Significant (p < 0.001) bodyweight loss also occurred with canagliflozin versus placebo during this period (mean 
changes from baseline −2.2 and −2.8 vs. −0.1 kg; overall baseline value 90 kg) [48]. Longer term, canagliflozin 100 or 
300 mg/day largely maintained improvements versus placebo in HbA1C levels (mean changes from baseline: −0.32 and 
−0.43 vs. +0.17%), as well as FPG levels and bodyweight, over 104 weeks in a 78-week extension (n = 624) [49]. 
Notably, canagliflozin (as monotherapy or combination therapy) improved glycaemic control versus placebo 
regardless of whether patients were aged ≥65 or <65 years (n = 445 and 1868) [50] or ≥75 or <75 years (n = 183 and 
3975) [51] in pooled analyses of four [50] or six [51] phase 3 trials (plus CANVAS substudies [51]) of 18–26 weeks’ 
duration. However, glycaemic improvements were slightly more pronounced in the younger patient groups [50, 51]. 
4.4.3 Other Patients 
In Asian patients with T2D, canagliflozin 100 or 300 mg/day, as first-line monotherapy [26, 52] or added to oral AHA 
[26, 53] or insulin [54] regimens, significantly (p < 0.05) improved HbA1C, FPG and bodyweight versus corresponding 
placebo regimens in phase 3 (or unspecified phase [54]) trials of 16–24 weeks’ duration (total n = 146–676), with 
improvements in these parameters also seen in a 52-week noncomparative study (total n = 1299; primary endpoint not 
specified) [26]. Indeed, in post hoc analyses, race did not impact the glycaemic or bodyweight benefits of canagliflozin 
regimens in placebo-controlled trials (pooled; n = 124–3108 per racial group) [55-59] or in one (n = 307) [56] or three 
(n = 551; pooled) [59] active comparator-controlled studies. 
Reductions in HbA1C and bodyweight (of ≈0.5 and ≈2%) were also seen with canagliflozin (100 or 300 mg/day) 
versus placebo in T2D patients with renal impairment (eGFR 45 to <60 mL/min/1.73 m
2
) in a pooled analysis (n = 721) 
of phase 3 trials; most (94%) patients in this analysis were receiving an AHA regimen at baseline [60]. Moreover, in 
patients with T2D who met metabolic syndrome criteria in two phase 3 trials (n = 1169 or 586; post hoc analysis), 
adding canagliflozin 100 or 300 mg/day to ongoing metformin-based therapy generally improved glycaemic (HbA1C, 
FPG) as well as non-glycaemic (e.g. bodyweight, BMI, waist circumference, BP, HDL-C) metabolic parameters over 52 
weeks relative to adding glimepiride or sitagliptin, although generally increased LDL-C levels [61]. 
 Additional Analyses 4.5
Canagliflozin (100 or 300 mg/day), as monotherapy or add-on therapy, was effective in lowering HbA1C levels in T2D 
patients, regardless of baseline patient/disease characteristics such as age [62], BMI [62], HbA1C level [63], T2D 
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duration [63] or renal function (although efficacy declined with increasing renal impairment) [62], in post hoc pooled 
analyses of four (n = 2313) [63] or six (n = 4053) [62] placebo-controlled phase 3 trials of 18–26 weeks’ duration. 
Moreover, post hoc analyses of composite endpoints have confirmed the concomitant benefit of canagliflozin on 
glycaemic and other metabolic parameters (e.g. bodyweight, BP and lipids) in T2D patients [29, 64-66]. For instance, a 
reduction in both HbA1C and bodyweight was achieved by 1.5- to 3.6-fold more recipients of canagliflozin (100 or 300 
mg/day) than of placebo [29], glimepiride [66] or sitagliptin [67], when each was used for 18 [29] or 52 [66, 67] weeks 
as add-on therapy to ongoing AHA regimens in CANVAS [29], CANTATA-SU [66] or two other phase 3 trials 
(pooled; n = 1856) [67]. Notably, combined reductions in bodyweight and HbA1C with canagliflozin may lead to 
improvements in liver enzyme levels in patients with T2D, according to additional pooled phase 3 study data [68]. 
 Real-World Studies 4.6
The efficacy of canagliflozin in the real-world setting has been established in various analyses of US healthcare claims 
databases and/or healthcare datasets [30-32, 69-71]. Among those fully published (n = 826–1562 evaluable) [69-71], 
canagliflozin regimens reduced (p < 0.001, where specified [69, 71]) HbA1C levels from baseline by a mean of 0.70–
0.81% and increased the proportion of patients achieving HbA1C levels <7.0% by approximately twofold (p < 0.001 
where specified [71]) over 6 months [69] or mean of 67–185 days [70, 71]. Limited glycaemic data available from the 
other analyses (n = 1227–16,163) [30-32] were generally consistent with these findings, with one indicating 
significantly (p = 0.004) greater reductions in HbA1C levels with canagliflozin than with DPP4 inhibitor regimens over 
≈183 days’ mean follow-up [32]. In another of these analyses (designed primarily to assess bodyweight), canagliflozin 
regimens were associated with significant (p < 0.0001) mean reductions from baseline in bodyweight, ranging from 
−1.8 kg at 3 months to −2.6 kg at 12 months in the overall population and −2.1 to −3.0 kg in patients with a baseline 
BMI of ≥30 kg/m2 [31]. 
5 Tolerability 
Oral canagliflozin, as monotherapy or add-on therapy, was generally well tolerated for up to 104 weeks in patients with 
T2D, including those of older age and/or at high CV risk, in the key phase 3 or 4 trials discussed in Sect. 4. In the 
pooled analysis of four placebo-controlled phase 3 trials (n = 2313) [72], treatment-related adverse events (AEs) 
occurred in up to 1.7-fold more canagliflozin 100 or 300 mg/day than placebo recipients over 26 weeks (20.5 and 22.9 
vs. 13.2%) and, consistent with canagliflozin’s mechanism of action (Sect. 2), the most common AEs associated with 
the drug were female genital mycotic infection (GMI) (10.4 and 11.4 vs. 3.2%), urinary tract infection (UTI) (5.9 and 
4.3 vs. 4.0%), increased urination (5.3 and 4.6 vs. 0.8%) and male GMI (4.2 and 3.7 vs. 0.6%). AEs were generally mild 
or moderate and few patients experienced serious AEs (≈3% in each group) or death (<0.3% in each group) [72].  
In active comparator-controlled studies, canagliflozin regimens were generally similar to sitagliptin or glimepiride 
regimens in terms of the incidence of treatment-related AEs (20–34 vs. 20–28%) and discontinuations because of AEs 
(3–7 vs. 3–6%) over 52 weeks [15, 34, 35], with 104-week data from the glimepiride-controlled trial being consistent 
with these findings [36]. Local prescribing information should be consulted for warnings and precautions relating to 
AEs such as diabetic ketoacidosis (rare but sometimes serious/fatal [7, 73]), elevated haematocrit, and GMIs [7]. 
 Genitourinary Infections 5.1
Canagliflozin increases UGE (Sect. 2), which may contribute to GMIs [7]. Canagliflozin 300 mg/day significantly (p < 
0.00001; 3.76-fold) increased the risk of GMIs versus placebo over 12–26 weeks in a meta-analysis of eight placebo-
controlled trials (n = 1338) [74]. The most common GMIs with canagliflozin (100 or 300 mg/day) over 26 weeks 
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included vulvovaginal mycotic infection in women (5.9 and 5.3 vs. 1.3% with placebo) and balantitis in men (2.2 and 
1.7 vs. 0%) in the pooled analysis of four placebo-controlled studies [72]. GMIs in this analysis were never serious, 
rarely (<1% of patients) led to therapy discontinuation and responded to standard antifungal treatment [72], lasting a 
median of 7 and 18 days in treated female and male canagliflozin recipients [75].  
The likelihood of GMIs with canagliflozin 300 mg/day was significantly greater (4.95-fold; p < 0.00001) than with 
sitagliptin or glimepiride over 12–52 weeks in a meta-analysis of four active comparator-controlled trials (n = 2510) 
[74]. Similarly, in individual studies, the GMI incidence was numerically greater with canagliflozin (100 or 300 
mg/day) than with sitagliptin or glimepiride regimens over 52 weeks both in men (2–9 vs. 0.5–1%) and women (10–15 
vs. 2–4%) [15, 34, 35], although did not further increase versus glimepiride over 104 weeks [36]. 
Despite being a common AE with canagliflozin, UTIs did not significantly differ in incidence between canagliflozin 
300 mg/day and placebo over 12–26 weeks in the meta-analysis of eight trials [74]. UTIs with canagliflozin (100 or 300 
mg/day), although often symptomatic, were rarely serious (≤0.2% of patients) [76] and responded to standard therapy 
without canagliflozin discontinuation [7] when four placebo-controlled studies were pooled. Compared with other 
active agents, the UTI incidence with canagliflozin did not significantly differ from that with sitagliptin or glimepiride 
in the meta-analysis of four 12- to 52-week trials [74], with data from individual sitagliptin- or glimepiride-controlled 
studies of up to 104 weeks’ duration generally supporting these findings [15, 34-36]. 
 Osmotic Diuresis and Volume Depletion  5.2
By increasing UGE, canagliflozin can trigger osmotic diuresis. Treatment-related AEs related to osmotic diuresis (e.g. 
increased urine volume/frequency) occurred in 6.1-fold more canagliflozin (100 or 300 mg/day) than placebo recipients 
(4.9 and 4.9 vs. 0.8%) in the pooled analysis of four 26-week trials (n = 2313) [40]; these AEs typically occurred during 
the first 6 weeks of therapy and none were serious [72]. Consistent with these findings, over 12–52 weeks, canagliflozin 
significantly (p < 0.01) increased the risk of osmotic diuresis-related AEs compared with placebo, as well as active 
comparators (sitagliptin or glimepiride), in meta-analyses (n = 3853 and 5057) [74]. 
AEs related to volume depletion (e.g. postural dizziness, orthostatic hypotension) were rare (≈1% incidence) with 
canagliflozin in the pooled analysis of four placebo-controlled trials [40] and occurred predominantly in patients on 
antihypertensives [72]. Moreover, these AEs did not significantly differ in incidence between canagliflozin and placebo 
or active comparators (sitagliptin or glimepiride) in meta-analyses (n = 3334 and 4910) [74]. When risk factors for 
volume depletion-related AEs were assessed in a pooled analysis of eight phase 3 trials (n = 9439), the incidence was 
generally numerically greater with canagliflozin 100 or 300 mg/day than with comparators in patients who were 
receiving loop diuretics (3.2 and 8.8 vs. 4.7%), had a baseline eGFR of 30 to <60 mL/min/1.73 m
2
 (4.8 and 8.1 vs. 
2.6%) or were aged ≥75 years (4.9 and 8.7 vs. 2.6%) [7]. Similarly, in CANVAS (in which patients generally had more 
T2D complications), the incidence of volume depletion-related AEs was 2.8 and 4.6% with canagliflozin 100 or 300 
mg/day versus 1.9% with placebo [7]. However, canagliflozin did not increase the incidence of volume depletion-
related AEs that were serious or that led to discontinuation in these studies [7]. 
Volume depletion with canagliflozin may reduce eGFR, although the reductions are usually small, occur in the first 
few weeks of therapy [7, 72] and stabilize/attenuate thereafter [72, 77]. However, large (>30%), albeit transient, eGFR 
reductions have occurred with canagliflozin in patients more susceptible to volume depletion (such as the high-risk 
patients already discussed), although did not usually require treatment interruption [7]. Renal-related AEs (e.g. reduced 
GFR, increased blood creatinine) occurred with an incidence of <3% and were rarely serious (≤0.2% of patients) with 
canagliflozin or comparators over 26 [72] or 104 [78] weeks’ therapy in pooled analyses of placebo- and/or active 
comparator-controlled trials [72, 78]. Nevertheless, a possible signal for acute renal injury was detected with 
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canagliflozin, as well as other SGLT2 inhibitors, when postmarketing data from the US FDA AE Reporting System 
were assessed [78]. 
 Hypoglycaemia 5.3
Hypoglycaemia was relatively uncommon when canagliflozin (100 or 300 mg/day) was used as monotherapy [13, 33] 
or added to metformin (alone [34] or in combination with sitagliptin [37] or pioglitazone [16]) over 26 weeks (3−4 vs. 
2−3% with placebo) or 52 weeks (4−7%) in placebo- and/or active comparator-controlled trials [13, 34, 37] and their 
extensions [16, 33]. In patients receiving metformin in active comparator-controlled studies, the incidence of 
hypoglycaemia with add-on canagliflozin (100 or 300 mg/day) was not markedly different from that with add-on 
sitagliptin (7 and 7 vs. 4%) [34] but was significantly (p < 0.0001) lower than with add-on glimepiride (6 and 5 vs. 
34%) [35] over 52 weeks, with the benefit over glimepiride maintained at week 104 [36]. Severe hypoglycaemia was 
rare (<1%) with canagliflozin in these trials, where specified [13, 16, 34-37]. 
By contrast, hypoglycaemia tended to be relatively common when canagliflozin was added to an AHA regimen that 
included a sulfonylurea [14, 15, 44] or insulin [43] in phase 3 trials. For instance, in patients receiving metformin plus a 
sulfonylurea, the incidence of hypoglycaemia over 52 weeks was approximately twofold greater with add-on 
canagliflozin 100 or 300 mg/day than with add-on placebo (34 and 37 vs. 18%) [14] but did not markedly differ 
between add-on canagliflozin 300 mg/day and sitagliptin (43 vs. 41%) [15]; severe hypoglycaemia was not common 
(≤4% incidence) in any treatment group of either trial. Added to insulin therapy, canagliflozin 100 or 300 mg/day did 
not significantly differ from placebo in terms of hypoglycaemia (59 and 57 vs. 48%) or severe hypoglycaemia (5 and 6 
vs. 4%) incidence over 52 weeks in CANVAS [43].  
 Cardiovascular and Other Events 5.4
Canagliflozin (100 or 300 mg/day, pooled) did not increase the risk of major CV events (MACE) relative to placebo 
and active comparators (combined) in a pre-specified interim meta-analysis of phase 2 or 3 trials (n = 9632; 44.9% were 
high CV risk patients from CANVAS). The hazard ratio (HR) was 0.91 (95% CI 0.68, 1.22) for the composite primary 
endpoint of time to CV death, non-fatal stroke, non-fatal myocardial infarction and unstable angina requiring 
hospitalization [7]. 
Lower limb amputations (mainly of the toes) appeared to increase in incidence with canagliflozin in T2D patients 
with, or at high risk of, CVD in ongoing long-term trials [7]. For instance, in an interim safety analysis of CANVAS 
(mean follow-up 4.5 years), lower limb amputation occurred with an approximately twofold greater incidence with 
canagliflozin 100 or 300 mg/day than with placebo (7 and 5 vs. 3 per 1000 patient-years) [79]. The mechanism 
underlying this risk has not yet been determined; patients at higher risk of amputation should be monitored and 
counselled appropriately, and canagliflozin may need to be discontinued if events such as skin ulcer, infection, 
osteomyelitis or gangrene develop in the lower extremities [7]. 
In addition, bone fracture risk was significantly increased with canagliflozin (100 or 300 mg/day, combined) relative 
to placebo over 104 weeks in CANVAS (n = 4327) (4.0 vs. 2.6% of patients; HR 1.51; 95% CI 1.04, 2.19), whereas 
pooled data from non-CANVAS studies found no significant fracture risk with these canagliflozin dosages over 52 (n = 
5867) or 104 (n = 2164) weeks versus placebo/active agents (combined) [80]. The reason for the increased fracture risk 
with canagliflozin in CANVAS but not the non-CANVAS studies is unknown, although differences in factors such as 
patient age (mean 62 vs. 58 years), loop diuretic use (12 vs. 4% of patients) and eGFR (mean 77 vs. 85 mL/min) have 
been suggested.  
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6 Dosage and Administration 
In the EU, canagliflozin is approved for use as monotherapy (as an adjunct to diet and exercise, when metformin is 
considered inappropriate) and as an add-on therapy (to other AHAs, including insulin) to improve glycaemic control in 
adults with T2D [7]. Canagliflozin tablets should be taken orally, preferably prior to the first food of the day. The initial 
dosage is 100 mg once daily; if tolerated (and eGFR is ≥60 mL/min/1.73 m2), this can be increased to 300 mg once 
daily if necessary. Care is advised if increasing the dosage in patients for whom the initial diuresis associated with the 
drug may pose a risk (e.g. those aged ≥75 years or with known CVD) [7]. Local prescribing information should be 
consulted for further details, including drug interactions, use in special patient populations, contraindications and other 
warnings and precautions. 
7 Place of Canagliflozin in T2D Management 
Managing T2D requires an individualized stepwise approach [1, 2], taking into consideration common patient 
comorbidities (e.g. heart failure, coronary artery disease) and the likelihood that AHA-associated hypoglycaemia 
(thought to contribute to CV dysfunction and, in high-risk patients, CV events) may have untoward outcomes [2]. 
Among the numerous AHAs now available, metformin monotherapy remains the standard first-line option for most 
patients [1, 2], although sequential addition of drugs from other classes is often required to attain/maintain good 
glycaemic control.  
Although most AHAs lower blood glucose levels by increasing insulin secretion and/or sensitivity, SGLT2 
inhibitors (e.g. canagliflozin, dapagliflozin and empagliflozin [81]) act independently of insulin, enabling them to be 
used at any stage of T2D (i.e. regardless of insulin secretory capacity) and to complement a wide variety of AHAs as 
part of combination regimens [2, 82]. In treatment guidelines, SGLT2 inhibitors (as well as sulfonylureas, 
thiazolidinediones, DPP4 inhibitors, GLP-1 RAs and insulin) are generally recommended as second- and/or subsequent-
line options for use in combination regimens, although can be used first line if metformin is contraindicated/not 
tolerated [1, 2] (provided a sulfonylurea or pioglitazone is inappropriate and a DPP4 inhibitor would otherwise be used 
[83]). 
Canagliflozin is one of the most widely available SGLT2 inhibitors [81]. Its approval as a first-line monotherapy or 
as an add-on to other AHAs, including insulin, in adults with T2D (Sect. 6) was based on numerous well-designed 
clinical trials in these settings, in which the drug (at 100 or 300 mg/day) provided improved and sustainable glycaemic 
control over up to 104 weeks’ therapy (Sect. 4). The glycaemic efficacy of canagliflozin 100 mg/day was noninferior to 
that of metformin as first-line monotherapy and to that of sitagliptin or glimepiride as an add-on therapy, whereas 
canagliflozin 300 mg/day was more effective than sitagliptin or glimepiride in the add-on setting (Sect. 4.1). Real-world 
data are also now available and support the use of canagliflozin in T2D management (Sect. 4.6). 
In addition to hyperglycaemia, the common comorbidities of T2D, such as obesity, hypertension and dyslipidaemia, 
should also be addressed to minimize the overall CV risk of T2D [84]. Canagliflozin (like other SGLT2 inhibitors) 
induces moderate bodyweight loss (Sect. 4.2) through urinary loss of glucose (and thus calories) (Sect. 2) [2, 82]. The 
ability to reduce bodyweight is shared by few other AHAs (including GLP-1 RAs), with most increasing bodyweight 
(e.g. sulfonylureas, meglitinides, thiazolidinediones and insulin) or being bodyweight neutral (e.g. DPP4 inhibitors, 
metformin, α-glucosidase inhibitors) [2, 85]; as such, canagliflozin has a bodyweight profile more favourable than that 
of glimepiride or sitagliptin as an add-on therapy (Sect. 4.2). Bodyweight losses occur with canagliflozin even in 
combination with AHAs typically associated with bodyweight gain, and appear primarily due to reductions in fat (Sect. 
4.2), which could (through improved insulin sensitivity) contribute to the glycaemic benefits of the drug. 
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Canagliflozin also appears to modulate various other non-glycaemic CVD risk factors, consistent with the SGLT2 
inhibitor class [2]. For instance, the drug generally improved BP (Sect. 4.3) (possibly through weight loss, osmotic 
diuresis and/or mild natriuresis [86]), serum uric acid levels (Sect. 2) (possibly via increased urinary secretion) and 
markers of arterial stiffness (Sect. 4.3). It also modestly impacted serum lipid levels (generally increasing HDL-C and 
LDL-C and reducing triglyceride; Sect. 4.3), although it is not yet clear whether the net impact of the drug on lipids is 
of any clinical relevance. 
However, the CV profile of canagliflozin is being investigated. At present, CV data for the drug are limited to a 
meta-analysis of T2D studies (including the large ongoing CV outcomes trial CANVAS), which demonstrated no 
increased MACE risk with canagliflozin (Sect. 5.4). Mature CV data from CANVAS are required to determine whether 
canagliflozin improves major CV outcomes in T2D patients at high CV risk, a benefit that has been seen with 
empagliflozin in a similar trial; to date, the only other AHAs to have demonstrated a reduction in MACE risk are GLP-1 
RAs [87]. Thus, CANVAS CV data are awaited with interest. 
Canagliflozin is generally well tolerated and, consistent with its mechanism of action, the most common AEs are 
genitourinary infections and increased urination (Sect. 5). As with other SGLT2 inhibitors and most other AHAs [2], 
hypoglycaemia is uncommon with canagliflozin, unless used in combination with drugs that increase the risk of the 
event (Sect. 5.3), among which are sulfonylureas, insulins and meglitinides [2]. 
Reductions in eGFR initially occur with canagliflozin due to volume depletion and may explain the signal of acute 
kidney injury identified with the drug (and other SGLT2 inhibitors) postmarketing (Sect. 5.2). However, over 104 
weeks, eGFR reductions with canagliflozin were less than those with glimepiride, suggesting kidney function 
preservation (Sect. 4.3), possibly via albuminuria and glomerular hyperfiltration attenuation [78]. Notably, the effects of 
the drug on renal and CV outcomes in T2D patients with diabetic nephropathy (CREDENCE; NCT02065791) or 
increased risk of CV events (CANVAS-R; NCT01989754) are currently being evaluated, as are its effects in T2D 
patients with congestive heart failure (CANDLE; UMIN000017669). Other AEs related to volume depletion (such as 
dizziness and orthostatic hypotension) are generally uncommon with canagliflozin, but may limit its use in patients 
particularly susceptible to volume depletion, such as the elderly or those on antihypertensives or with CVD (Sect. 5.2); 
thus, any volume depletion should be corrected before initiating canagliflozin [7]. Further longer-term studies 
evaluating the benefits versus potential risks of canagliflozin and other SGLT2 inhibitors would be beneficial, including 
the potential for lower-limb amputations and bone fractures (Sect. 5.4). 
Also of interest are robust trials directly comparing canagliflozin with AHAs such as other SGLT2 inhibitors or 
GLP-1 RAs. Currently, such comparisons are limited to network meta-analyses, across which canagliflozin was at least 
as effective in improving glycaemic control over 26 (or 26–104 [88]) weeks as empagliflozin [88-90], dapagliflozin 
[88-90], sitagliptin, pioglitazone or a sulfonylurea [90], when used as monotherapy [90] or as part of a dual [88] or 
triple [89] AHA regimen. Similar comparisons (including those vs. GLP-1 RAs) had more mixed findings, depending 
on the canagliflozin/comparator dosage and the timepoint and/or treatment setting assessed [91, 92]. Due to their 
indirect nature, findings from such analyses should be interpreted with caution. 
Like most AHAs, canagliflozin and other SGLT2 inhibitors have the convenience of oral administration (unlike 
GLP-1 RAs and insulins, which are injectable), although the cost of SGLT inhibitors and other relatively recent AHA 
classes (e.g. DPP4 inhibitors, GLP-1 RAs) is high [2]. Various canagliflozin cost-utility analyses conducted from the 
NHS perspective of the UK [93, 94] or Spain [95, 96] are available. Their findings suggest that canagliflozin 100 mg 
may dominate (i.e. be cheaper with greater quality-adjusted life-year gains) and canagliflozin 300 mg may be cost 
effective versus both empagliflozin 25 mg and dapagliflozin 10 mg as monotherapy [94] and versus sitagliptin 100 mg 
as an add-on to metformin [96]. Both canagliflozin dosages may also dominate dapagliflozin 10 mg [95] and be cost 
effective versus a sulfonylurea [93] in the latter setting, and dominate sitagliptin as an add-on to metformin plus a 
sulfonylurea [96]. Additional cost analyses conducted in the UK [97] and from an Italian NHS perspective [98] 
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generally support these findings, with canagliflozin estimated to be cost saving versus other SGLT inhibitors [97], as 
well as sitagliptin and glimepiride [98], when used as add-on therapy. Further cost-utility analyses would be beneficial. 
In conclusion, canagliflozin is an effective and generally well tolerated once-daily oral AHA for T2D management, 
with an insulin-independent mechanism of action that makes it a particularly useful option for use in combination 
regimens. Given the drug improves glycaemic control, as well as bodyweight and BP, and has a low risk of 
hypoglycaemia, its CV profile is highly anticipated. 
 
Data selection sources: Database(s): EMBASE, MEDLINE and 
PubMed from 1946 to present. Clinical trial registries/databases 
and websites were also searched for relevant data [searches last 
updated 12 May 2017]. Records were limited to those in English 
language. 
Search terms: Canagliflozin, Canaglu, Invokana, JNJ-
28431754, TA-7284, type 2, type II, T2DM, T2D 
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Table 1 Efficacy of oral canagliflozin as first-line monotherapy in adults with inadequately-controlled T2D in 26-week double-blind phase 3 
trials and a 26-week double-blind extension; changes from baseline are least squares means and baseline values are means 
Study Regimen (mg od) 
[no. of pts] 
Week 
of eval 
Change from BL [BL] % pts with 
HbA1C <7% 
Change from BL 
[BL] 
   HbA1C
a
 (%) FPG (mmol/L)  Bodyweight (kg) 
Stenlöf et al [13] CAN 100 [195] 26 −0.77* [8.1] −1.5* [9.6] 44.5* −2.5* [85.9] 
(CANTATA-M) CAN 300 [197]  −1.03* [8.0] −1.9* [9.6] 62.4* −3.4* [86.9] 
 PL [192]  +0.14 [8.0] +0.5 [9.2] 20.6 −0.5 [87.5] 
Stenlöf et al [33] CAN 100 [166] 52 −0.81 [8.0] −1.5 [9.5] 52.4 −2.8 [86.4] 
(CANTATA-M ext)
b
 CAN 300 [166]  −1.11 [8.0] −2.2 [9.4] 64.5 −3.9 [87.2] 
Jodar et al [27] CAN 100 [712
c
] 26 −1.37d [8.8c] NR 38.8 NR 
 CAN 300  −1.42d NR 42.8 NR 
 MET-XR  −1.30 NR 43.0 NR 
 
BL baseline, CAN canagliflozin, ext extension, eval evaluation, FPG fasting plasma glucose, HbA1C glycosylated haemoglobin, MET-XR metformin-
extended release, NR not reported, od once daily, PL placebo, pts patients 
* p < 0.001 vs. PL
 
a Primary endpoint at week 26  
b Pts (n = 155) originally randomized to PL in CANTATA-M were switched to sitagliptin 100 mg od for this ext; efficacy data were not reported 
c Value is for the whole trial population 
d Noninferiority of CAN 100 or 300 mg od vs. MET-XR was established (no further details reported) 
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Table 2 Efficacy of oral canagliflozin as add-on therapy to metformin, with or without other oral antihyperglycaemic agents, in adults with 
inadequately-controlled T2D in randomized, double-blind, phase 3 (or phase 4 [37]) trials and a double-blind extension 
Study (acronym) Regimen (mg od) [no. of pts] Week 
of eval 




Change from BL 
[BL] 
   HbA1C
a
 (%) FPG (mmol/L) Bodyweight (kg) 
Add-on to MET       
Lavalle-González et al [34] CAN 100 + MET [368] 26 −0.79** [7.9] −1.5** [9.4] 46** −3.3** [88.7] 
(CANTATA-D) CAN 300 + MET [367]  −0.94** [8.0] −2.1** [9.6] 58** −3.6** [85.4] 
 SIT 100 + MET [366]  −0.82
b
 [7.9] −1.1
b [9.4] 55b −1.1b  [87.6] 
 PL + MET [183]  −0.17 [8.0] +0.1 [9.1] 30 −1.1 [86.7] 
 CAN 100 + MET [368] 52 −0.73
c
 [7.9] −1.5† [9.4] 41
d
 −3.3† [88.7] 
 CAN 300 + MET [367]  −0.88
c
 [8.0] −2.0† [9.6] 55d −3.7† [85.4] 
 SIT 100 + MET [366]  −0.73 [7.9] −1.0 [9.4] 51 −1.2 [87.6] 
Cefalu et al [35] CAN 100 + MET [483] 52 −0.82
c
 [7.8] −1.35b [9.2] 54b −3.7††
e
 [86.8] 
(CANTATA-SU) CAN 300 + MET [485]  −0.93
c
 [7.8] −1.52b [9.1] 60b −4.0††e [86.6] 
 GLIM + MET [482]  −0.81 [7.8] −1.02 [9.2] 56 +0.7 [86.6]  
Leiter et al [36] CAN 100 + MET [393] 104 −0.65 [7.8] −1.1f [9.2] 43b −4.1f [86.8] 
(CANTATA-SU ext) CAN 300 + MET [377]  −0.74
f
 [7.8] −1.3f [9.1] 50b −4.2f [86.6] 
 GLIM + MET [381]  −0.55 [7.8] −0.6 [9.2] 44 +0.9 [86.6]  
Add-on to MET + Other Oral Antihyperglycaemic Agent     
Wilding et al [14] CAN 100 + MET + SU [157] 26 −0.85** [8.1] −1.0** [9.6] 43** −1.9**e [93.5] 
(CANTATA-MSU) CAN 300 + MET + SU [156]  −1.06** [8.1] −1.7** [9.3] 57** −2.5**e [93.5] 
 PL + MET + SU [156]  −0.13 [8.1] +0.2 [9.4] 18 −0.8 [90.8] 
 CAN 100 + MET + SU [157] 52b −0.74 [8.1] −1.1 [9.6] 39 −2.0 [93.5] 
 CAN 300 + MET + SU [156]  −0.96 [8.1] −1.5 [9.3] 53 −3.1 [93.5] 
 PL + MET + SU [156]  +0.01 [8.1] +0.6 [9.4] 19 −1.0 [90.8] 
Schernthaner et al [15] CAN 300 + MET + SU [377] 52 −1.03
c
 [8.1] −1.7** [9.4] 48b −2.3** [87.6] 
(CANTATA-D2) SIT 100 + MET + SU [378]  −0.66 [8.1] −0.3 [9.1] 35 +0.1 [89.6] 
Forst et al [16] CAN 100 + MET + PIO [113] 26 −0.89** [8.0] −1.5** [9.4] 47* −2.6** [94.2] 
 CAN 300 + MET + PIO [114]  −1.03** [7.8] −1.8** [9.1] 64** −3.7** [94.4] 
 PL + MET + PIO
g
 [115]  −0.26 [8.0] +0.1 [9.1] 33 −0.2 [94.0] 
 CAN 100 + MET + PIO [103] 52 −0.92 [8.0] −1.5 [9.4] 52 −2.5 [94.2] 
 CAN 300 + MET + PIO [96]  −1.03 [7.8] −1.8 [9.1] 66 −3.6 [94.4] 
Rodbard et al [37] CAN
h
  + MET + SIT [107] 26 −0.91** [8.5] −1.7** [10.3] 32** −3.1**e [93.8] 
 PL + MET + SIT [106]  −0.01 [8.4] −0.1 [10.0] 12 −1.6 [89.9] 
Changes from BL are least squares means and BL values are means  
BL baseline, BGD between-group difference, CAN canagliflozin, ext extension, eval evaluation, FPG fasting plasma glucose, GLIM glimepiride 
(uptitrated to 6 or 8 mg od), HbA1C glycosylated haemoglobin, MET metformin (generally ≥2000 mg/day; ≥1500 mg/day if higher dosages not 
tolerated, od once daily, PIO pioglitazone (30 or 45 mg/day), PL placebo, pts patients, SIT sitagliptin, SU sulfonylurea (≥50% maximal dosage) 
* p < 0.01, ** p ≤ 0.001 vs. PL; † p < 0.001, †† p < 0.0001 vs. active comparator group
 
a
 Primary endpoint at week 26 [14, 16, 34, 37] or 52 [15, 35] 
b
 No formal statistics performed/reported for CAN vs. PL [14], GLIM [35, 36] or SIT [15], or SIT vs. PL [34], for these endpoints/timepoints 
c
 Based on prespecified criteria, CAN 100 was noninferior to, and CAN 300 more effective than, SIT [15, 34] and GLIM [35] 
d Difference vs. SIT was not significant for CAN 300 but significant for CAN 100, based on the 95% CIs of the odds ratios 
e P-values are for percentage changes in bodyweight, and are assumed to also apply to kg changes 
f Significantly favoured CAN vs. GLIM, based on 95% CI for BGD 
g Ninety pts in this group entered the 26-week ext, during which they received SIT + MET + PIO to maintain blinding 
h Pts received CAN 100 or 300 mg od; pooled data for these groups are presented 
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Table 3 Efficacy of oral canagliflozin as add-on therapy to insulin- or incretin mimetic-based therapy or sulfonylurea monotherapy in 
prespecified [43, 44] or post hoc [45] subgroup analyses of the phase 3 CANVAS trial  
Regimen (mg od) [no. of pts] Week 
of 
eval 


















Add-on to INS therapy [43]       
CAN 100 + INS ± OAA [661] 18 −0.63a [8.3] −0.62** NR [9.2] −1.2** 19.8** NR [94.4] −1.9** 
CAN 300 + INS ± OAA [660]  −0.75a [8.3] −0.73** NR [9.2] −1.6** 25.8** NR [94.8] −2.4** 
PL + INS ± OAA [636]  −0.1a [8.3]  NR [9.2]  8.3 NR [94.8]  
CAN 100 + INS ± OAA [664] 52 −0.55 [8.3] −0.58b NR [9.2] −1.1b 23.2 NR [94.4] −2.8b 
CAN 300 + INS ± OAA [664]  −0.69 [8.3] −0.73b NR [9.2] −1.5b 28.6 NR [94.8] −3.5b 
PL + INS ± OAA [639]  +0.03 [8.3]  NR [9.2]  9.9 NR [94.8]  
Add-on to SU [44]        
CAN 100 + SU [42] 18 −0.70 [8.3] −0.74** −1.4 [10.3] −2.1 25 −0.6 [85.1] −0.4% 
CAN 300 + SU [40]  −0.79 [8.3] −0.83** −2.0 [9.8] −2.7** 33 −2.0 [80.4] −1.8%* 
PL + SU [45]  +0.04 [8.5]  +0.7 [10.3]  5 −0.2 [85.5]  
Add-on to incretin-mimetic therapy [45]      
CAN 100 + DPP4i ± OAA [103] 18 −0.46 [8.1] −0.56b NR −1.1b 22 −2.7 [91.5] −2.0b 
CAN 300 + DPP4i ± OAA [111]  −0.64 [8.0] −0.75b NR −1.5b 34b −3.5 [92.4] −2.7b 
PL + DPP4i ± OAA [102]  +0.1 [8.1]  NR  15 −0.8 [88.6]  
CAN 100 + GLP-1ra ± OAA [35] 18 −0.83 [8.2] −1.00b NR −1.8b 29b −3.3 [109] −2.7b 
CAN 300 + GLP-1ra ± OAA [30]  −0.89 [8.3] −1.06b NR −2.5b 35b −3.9 [111] −3.3b 
PL + GLP-1ra ± OAA [30]  +0.17 [7.9]  NR  7 −0.6 [106]  
Changes from BL are least squares means, BL values are means. INS dosage was ≥20 IU/day; SU, DPP4i and GLP-1ra dosages were stable 
BL baseline, CAN canagliflozin, diff difference, DPP4i dipeptidyl peptidase 4 inhibitor, eval evaluation, FPG fasting plasma glucose, GLP-1ra 
glucagon-like peptide-1 receptor agonist,  HbA1C glycosylated haemoglobin, INS insulin, NR not reported, OAA other antihyperglycaemic agent, od 
once daily, PL placebo, pts patients, SU sulfonylurea 
* p < 0.02, ** p < 0.001 vs. PL 
 
a Estimated from a graph 
b
 Between-group difference significantly favoured CAN regimen based on the 95% CI (p-values not available, as outcome was not 
prespecified [43, 44] or the analysis did not perform statistical testing for CAN vs. PL [45]) 
